Top image

Members' Meeting and Research Showcase

Research Showcases
Chris O'Brien Lifehouse
Sydney Catalyst

Sydney Catalyst marked the end of our original CINSW TCRC grant by providing members with the chance to come together on Thursday 11 August at our Members' Meeting and Research Showcase.


With no less than 16 Sydney Catalyst flagship projects on the program, approximately 70 members joined us for lunch before hearing brief updates from a broad range of projects from across the translational spectrum.

Professor Madeleine King guided us through the T2/T3 Research Showcase, which featured a diverse selection of research updates including an overview of Associate Professor Anne Cust's pilot randomised controlled trial of giving information on personalised genomic risk of melanoma to the public and its impact on sun protection and skin examination behaviours, to Dr Deme Karikios' PhD research into the costs and effectiveness of anti-cancer treatments (just to name a few).

After a well-earned afternoon tea break, we were then treated to a T1/T2 Research Showcase chaired by Professor Philip Hogg and featuring the latest findings across a range of research programs including Professor David McKenzie's efforts to develop and test novel nanoparticle drug carriers for externally triggered and targeted chemotherapy and Professor David Thomas' call to action for new biomarkers and targeted treatments to be incorporated in the cancer molecular screening and therapeutics program (MoST).

 What became obvious across both the T2/T3 and T1/T2 sessions is that Sydney Catalyst is fortunate to include a large and diverse group of incredibly dedicated and talented cancer clinicians, researchers, and students working toward our common goal of improving outcomes for people affected by cancer. We discussed this specifically during the final session of the day, the aim of which was for the our Governing Council, Scientific Advisory Committee and the Sydney Catalyst Team in general, to seek input on our draft strategic plan for our next five years.